Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2− advanced breast cancer receiving first-line ribociclib plus fulvestrant

被引：0
作者：
P. Neven
P. A. Fasching
S. Chia
G. Jerusalem
M. De Laurentiis
S.-A. Im
K. Petrakova
G. V. Bianchi
M. Martín
A. Nusch
G. S. Sonke
L. De la Cruz-Merino
J. T. Beck
J. P. Zarate
Y. Wang
A. Chakravartty
C. Wang
D. J. Slamon
机构：
[1] Universitair Ziekenhuis Leuven,Multidisciplinary Breast Centre
[2] University Hospital Erlangen,Cancer Research Institute, Seoul National University Hospital
[3] Friedrich-Alexander University Erlangen-Nuremberg,Fondazione Istituto di Ricovero e Cura a Carattere Scientifico
[4] British Columbia Cancer Agency,Instituto de Investigación Sanitaria Gregorio Marañon, Centro de Investigación Biomédica en Red de Cáncer, Grupo Español de Investigación en Cáncer de Mama
[5] CHU Liege and Liège University,undefined
[6] Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale”,undefined
[7] Seoul National University College of Medicine,undefined
[8] Masaryk Memorial Cancer Institute,undefined
[9] Istituto Nazionale dei Tumori,undefined
[10] Universidad Complutense,undefined
[11] Practice for Hematology and Internal Oncology,undefined
[12] Netherlands Cancer Institute/Borstkanker Onderzoek Groep Study Center,undefined
[13] Hospital Universitario Virgen Macarena,undefined
[14] Highlands Oncology,undefined
[15] Novartis Pharmaceuticals Corporation,undefined
[16] Novartis Pharma AG,undefined
[17] David Geffen School of Medicine at UCLA,undefined
来源：
Breast Cancer Research | / 25卷
关键词：
Ribociclib; CDK4/6 inhibitor; Advanced breast cancer; Overall survival; First line;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 75 条
[1]  
Pernas S(2018)CDK4/6 inhibition in breast cancer: current practice and future directions Ther Adv Med Oncol 10 1758835918786451-1649
[2]  
Tolaney SM(2020)5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) Ann Oncol 31 1623-1936
[3]  
Winer EP(2016)Palbociclib and letrozole in advanced breast cancer N Engl J Med 375 1925-3646
[4]  
Cardoso F(2017)MONARCH 3: abemaciclib as initial therapy for advanced breast cancer J Clin Oncol 35 3638-1748
[5]  
Paluch-Shimon S(2016)Ribociclib as first-line therapy for HR-positive, advanced breast cancer N Engl J Med 375 1738-915
[6]  
Senkus E(2018)Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial Lancet Oncol 19 904-2472
[7]  
Finn RS(2018)Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3 J Clin Oncol 36 2465-1936
[8]  
Martin M(2022)Overall survival with first-line palbociclib plus letrozole versus placebo plus letrozole in women with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer: analyses from PALOMA-2 J Clin Oncol 40 LBA1003-3442
[9]  
Rugo HS(2022)LBA15 MONARCH 3: interim overall survival (OS) results of abemaciclib plus a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+, HER2-advanced breast cancer (ABC) Ann Oncol 33 S1384-124
[10]  
Goetz MP(2018)Overall survival with palbociclib and fulvestrant in advanced breast cancer N Engl J Med 379 1926-950
12345678